ArticleThe Lancet regional health. Europe2026
Weight and HbA1c trajectories following initiation of continuous glucose monitoring in adults with type 1 diabetes: a cohort study using group-based multi-trajectory analysis.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Continuous glucose monitoring (CGM) improves glycaemic management in adults with type 1 diabetes (T1D), but may be associated with weight gain. We assessed changes in body weight and HbA1c after CGM initiation and characterized weight-glycemia trajectories. Methods: We retrospectively analysed 4178 adults with T1D initiating CGM from the DPV registry (DPV-CGM; n = 2104) and a pooled Belgian cohort (BE-CGM; n = 2074). Outcomes over 24 months were evaluated using paired t-tests and group-based multi-trajectory modelling. In DPV, CGM initiators were compared with matched controls without CGM (n = 2104; matched for sex, age, diabetes duration, baseline weight, and HbA1c). Findings: After 24 months, mean body weight increased by 1.8 kg [95% CI: 1.5; 2.0] in DPV-CGM and 1.0 kg [0.8; 1.2] in the BE-CGM cohort, while HbA1c decreased by -0.2% [-0.1; -0.2] and -0.1% [-0.03; -0.1], respectively (all p < 0.0001). In DPV-controls, weight increased by 1.2 kg [0.9; 1.5] (p < 0.01) and HbA1c decreased by 0.06% [-0.001; -0.11] (p = 0.05). Three trajectories were identified. The first showed modest weight gain with HbA1c improvement: 147/2104 (7.0%) DPV-CGM vs 99/2104 (4.7%) DPV-controls, and 411/2074 (19.8%) in BE-CGM. The second, largest group, showed stable weight and HbA1c: 1773/2104 (83.2%) DPV-CGM vs 1612/2104 (74.7%) controls in DPV-controls, and 1447/2074 (69.8%) in BE-CGM. The third, an unfavourable trajectory characterized by substantial weight gain (≈8 kg) with stable HbA1c, included 184/2104 (9.9%) DPV-CGM vs 393/2104 (20.5%) DPV-controls, and 216/2074 (10.4%) in BE-CGM (ꭓ Interpretation: CGM initiation was associated with modest weight gain and improved HbA1c. Compared with matched controls, CGM users were less likely to belong to the unfavourable weight gain with stable HbA1c trajectory, which occurred in 9.9% vs 20.5%, respectively. Funding: Innovative Medicines Initiative2 Joint Undertaking under grant agreement No. 875534.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.